Buying guide
Versius vs Hugo RAS in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
Neither Versius nor Hugo RAS leads across the verified dimensions on DEPLOY's record as of 2026; the comparison table holds every sourced figure side by side.
| Attribute | ||
|---|---|---|
| Manufacturer | CMR Surgical | Medtronic |
| Form factor | surgical | surgical |
| Maturity | commercial | commercial |
| Autonomy | ◐ not independently verified | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | $750,000-$1,000,000 (analyst estimate) | Not announced |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 4 | 4 |
| Privacy practices | — | — |
| Sources on file | 24 | 18 |
Track this matchup
Get told the moment Versius or Hugo RAS changes. Verified changes only, the second they are real. No press-release noise.
Versius
Hugo RAS
Editorial summaries
Versius
CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot from UK-based CMR Surgical, and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data.
On regulatory status (a correction worth recording): Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025 (also cholecystectomy) and a gynecology 510(k) submitted April 29, 2026 (pending); it is not broadly 'US-pending', only the gynecology indication is. It is CE-marked and commercial across Europe, Latin America, AMEA, and Australia. As enterprise B2B surgical equipment sold to hospitals, there is no consumer price.
Hugo RAS
Medtronic's Hugo RAS is a modular, multi-port teleoperated robotic-assisted-surgery system and the main commercial competitor to Intuitive's da Vinci. It is CE-marked in Europe (urology and gynecology, October 2021) and US FDA-cleared for urology only (December 2025: prostatectomy, nephrectomy, cystectomy); US general-surgery and gynecology indications are planned but not yet cleared.
It is teleoperated with no shipped intraoperative AI. Medtronic does not disclose a Hugo installed-base count, so DEPLOY records honest absence rather than an invented number. It is enterprise B2B equipment; there is no consumer price.
Common questions
How do Versius and Hugo RAS differ?
What is the difference between Versius and Hugo RAS?
Is Versius or Hugo RAS more autonomous?
Recent coverage
- Medtronic to unveil Touch Surgery Aide compute platform at SRS 2026Hugo RAS · Ben Smith, Deploy Editor · 2026-07-21
- Pacemaker manufacturer Medtronic warns patients cybercrooks may have swiped health dataHugo RAS · The Register · 2026-07-02
- CMR Surgical secures 510k clearance of Versius Plus robotic surgical systemVersius · Ben Smith, Deploy Editor · 2026-06-09
- FDA Clears New Robotic Platform for Gallbladder SurgeryVersius · Ben Smith, Deploy Editor · 2025-12-17
Related comparisons
- Versius vs da Vinci (and Ion)
- Versius vs Stryker Mako SmartRobotics
- Versius vs mBos TKA System
- Versius vs Maestro
- Versius vs Johnson & Johnson Ottava
- Versius vs CORI
- Versius vs ROSA
- da Vinci (and Ion) vs Hugo RAS
- Stryker Mako SmartRobotics vs Hugo RAS
- Hugo RAS vs mBos TKA System
- Hugo RAS vs Maestro
- Hugo RAS vs Johnson & Johnson Ottava
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.